PhRMA Urges Fed. Circ. To Rethink Novo Patent Obviousness
The Federal Circuit put future innovation at risk earlier this year when it invalidated a Novo Nordisk A/S patent related to diabetes drug Prandin on obviousness grounds, trade group Pharmaceutical Research...To view the full article, register now.
Already a subscriber? Click here to view full article